The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...

A chip smaller than one square millimeter stores 160 holographic images at arbitrary 3D coordinates, with each spatial ...

The movement of waves, patterns that carry sound, light or heat, through materials has been widely studied by physicists, as ...

Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical ...

Welcome, everyone, to the JPMorgan Healthcare Conference. We are pleased to have with us the Almirall management team here with us today, Carlos Gallardo, Chairman and CEO; Karl Ziegelbauer, CFO; Jon ...

Currently, Kyocera’s technology enables aerial images whose focal positions vary by wavelength. In the future, increasing the ...

In January 2022, Garutadustat, the innovative, potentially best-in-class, oral PHD inhibitor was nominated as a preclinical ...

A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...

Lysoway Therapeutics, Inc., a biotechnology company advancing structure-guided small-molecule modulators of lysosomal ion ...

A new study published in The Journal of Neuroscience provides neural evidence regarding how environmental cues can bias human ...

Insilico Medicine (3696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of ...